Association of HLA class I and II genes with Middle East respiratory syndrome coronavirus infection in Koreans

In-Cheol Baek¹ | Eun-Jeong Choi¹ | Dong-Hwan Shin¹
Hyung-Jae Kim¹ | Haeyoun Choi² | Hyoung-Shik Shin³
Dong-Gyun Lim⁴ | Tai-Gyu Kim¹,²

¹Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea
²Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea
³Department of Infectious Diseases, College of Medicine, Eulji University, Daejeon, Seogu, Korea
⁴Translational Research Center, Research Institute of Public Health, National Medical Center, Seoul, Korea

Abstract

Introduction: Middle East Respiratory Syndrome (MERS) caused by MERS-coronavirus (CoV) is a lower respiratory tract disease characterized by a high mortality rate. MERS-CoV spread from Saudi Arabia to other countries, including South Korea. Dysfunction of the human leukocyte antigen (HLA) system has many effects due to genetic complexity and its role in the adaptive immune response. We investigated the association of HLA class I and II alleles with MERS-CoV in 32 patients with MERS.

Methods: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 were genotyped by polymerase chain reaction sequence-based typing.

Results: HLA-DQB1*03:02 are significantly associated with moderate/mild cases of MERS-CoV. Other alleles are no statistical significance.

Conclusions: Treatment strategies based on current research on the HLA gene and MERS-CoV will provide potential therapeutic targets.

KEYWORDS
HLA, MERS, MERS-CoV, Middle East respiratory syndrome coronavirus
Middle East Respiratory Syndrome (MERS) is a lower respiratory tract disease reported in Saudi Arabia, and it has since spread to other countries. From 2013 to April 2018, a beta-coronavirus of MERS infection (MERS-CoV) was identified in dromedaries (Camelus dromedarius) in the field. Serological evidence in 20 countries and molecular evidence in 13 countries was found for viral circulation.

South Korea is the most common location of MERS-CoV infection outside the Arabian Peninsula by June 19, 2015. There is an approximately 21% risk of death in all cases of MERS (95% reliable interval: 14-31). The interhospital spread began in one hospital and expanded to 17 hospitals in South Korea. The outbreak occurred entirely in hospitals and was primarily caused by infection control and policy failures. The average age of patients with MERS in South Korea was 55 years (global average: 50 years). Men were more affected than women in most countries, including South Korea. Most of the South Korean patients were infected at hospital and no community infections occurred. Respiratory disease, cancer, and hypertension were the main underlying diseases.

The dysfunction of the human leukocyte antigen (HLA) system, the cause of many clinical disorders, has a wide range of effects due to genetic complexity as well as the role of adaptive immune response system. MERS-CoV was investigated based on insights into the epidemiology and pathogenesis of the novel coronavirus of severe acute respiratory syndrome (SARS-CoV). Therefore, studies on the association of genetic variants including HLA with SARS or MERS has been ongoing. No HLA allele association was found in 95 Chinese patients with SARS. In the association study between HLA and SARS, HLA (p < 0.05). HLA-DRB1*12:02 of Vietnamese had association with SARS. HLA-B*46:01 was associated with SARS in Taiwanese patients (p = 0.0008; P< 0.0279). In Taiwan, the odds ratio (OR) of SARS in people with the homozygous or heterozygous HLA-C*08:01 genotype was 4.4 (95% confidence interval [CI], 1.5–12.9; p = 0.007). In another Taiwanese group, HLA-B*46:01 was associated with the severity of SARS (P = 0.0279) after selecting only the "serious case" patient group compared with the high-risk health-care practitioner group in the infected "SARS latent." HLA-B*07:03 frequencies in the SARS-CoV group were significantly higher than those in the control group (OR = 4.08; 95% CI, 2.03–8.18; p = 0.00072; P = 0.00022), and the HLA-DRB1*03:01 allele had a protective effect against SARS-CoV infection (OR = 0.06; 95% CI, 0.01-0.47; p = 0.00008; P< 0.0042) in Chinese patients. In the Saudi Arabian population, HLA-DRB1*11:01 and DQB1*02:02, HLA class II alleles, were associated with MERS-CoV, but this was not related to the outcome of the disease. It is unclear whether the Korean case population is associated with a host genetic predisposition, such as HLA. In this study, we investigated the association of HLA class I and II alleles with MERS-CoV.

This study comprised 32 patients with MERS admitted to or followed up after recovery at the National Medical Center in Seoul, South Korea. All patients were confirmed to have MERS-CoV infection by real-time reverse-transcription polymerase chain reaction (Real Time RT-PCR) of nasopharyngeal swabs or tracheal aspirates. The patients were classified into two groups depending on the clinical severity during their acute stage of infection. Severe disease (n = 16) included fatalities and patients who required mechanical ventilation to relieve respiratory failure. Moderate and mild disease (Mo/Mi) encompassed patients who reported symptoms such as fever, headache, cough, and malaise with or without pulmonary lesions in the absence of pulmonary failure. Demographic characteristics of the patients are shown in Table 1. Peripheral blood was collected from patients at the acute/convalescent phases of infection or after recovery. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized whole blood by density gradient centrifugation using Ficoll-Paque solution (GE Healthcare) and stored in liquid nitrogen until use. The study was approved by the NMC Ethical Committee and written informed consent was obtained from the patients (institutional review board [IRB]: H-1801-086-002, H-1712-085-005).

The control group included 142 genetically unrelated healthy Korean adults with no history of MERS and little

| TABLE 1 Characteristics of patients with MERS |
|---------------------------------------------|
| Group (clinical severity)                    |
| Moderate/Severe Total                        |
| No. of patients (%)                         | 16 (50) | 16 (50) | 32 |
| Male/female (n)                             | 8/8     | 13/3    | 21/11 |
| Age (year), mean ± SD                       | 50 ± 21 | 58 ± 15 | 54 ± 19 |
| Underlying disease, n (%)                   |         |         |       |
| Diabetes                                    | 1 (6.3) | 3 (18.8) | 4 (12.5) |
| Chronic renal disease                       | 1 (6.3) | 2 (12.5) | 3 (9.4) |
| Chronic cardiac disease                     | 1 (6.3) | 4 (25.0) | 5 (15.6) |
| Chronic pulmonary disease                   | 0 (0)   | 1 (6.3)  | 1 (3.1)  |
| Hypertension                               | 2 (12.5) | 7 (43.8) | 9 (28.1) |
| Chronic liver disease                       | 1 (6.3) | 0 (0)   | 1 (3.1)  |
| Solid tumor                                 | 2 (12.5) | 2 (12.5) | 4 (12.5) |
| Obesity                                     | 0 (0)   | 1 (6.3)  | 1 (3.1)  |

Abbreviation: MERS, Middle East Respiratory Syndrome.
or no gender distribution (age: 30–39 years; 70 females and 72 males). The control subjects provided written informed consent to participate and were mainly of comprised students and staff from the Medical College of the Catholic University of Korea and Hematopoietic Stem Cell Transplantation Center. The use of the material was reviewed and approved by the local institutional review board (IRB) of The Catholic University of Korea with written informed consent obtained for all samples collected (IRB: MC13SISI0126).

Genomic DNA was isolated from PBMCs by using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions. DNA yields and purity were determined by measuring the absorbance at 260 and 280 nm with a spectrophotometer (Nanodrop 2000, Thermo Scientific).

The paired primers have previously been reported. PCR conditions and direct sequencing methods used were those described by Shin et al. Genotyping of HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 was performed using PCR-sequence-based typing (PCR-SBT) methods. PCR was performed as recommended by the 13th International Histocompatibility Workshop.

Statistical significance was determined using the χ² test and Fisher's exact test. We corrected the p-values using Bonferroni's method and calculated the OR using Haldane's modification of Woolf's method. Each SNP was analyzed against the Hardy–Weinberg equilibrium of the control group using SNPStats (http://bioinfo.iconcologia.net/snpstats/start.htm) (p > 0.05).

HLA-DQB1*03:02 showed a significant association with Mo/Mi cases of MERS-CoV infection (OR = 4.8; 95% CI, 1.65–13.95; p = 0.002; Pc = 0.030). The HLA-C*01:02 allele frequency decreased in the Mo/Mi cases compared with in the controls but did not show statistical significance by Bonferroni's correction (OR = 0.1; 95% CI, 0.017–0.108; p = 0.015; Pc = NS). In Mo/Mi cases of MERS-CoV infection, the frequencies of HLA-C*12:02, -DRBI*04:06, and -DRBI*14:03 alleles were higher than those in the controls, but were not statistically significant by Bonferroni's correction ([C*12:02] OR = 5.2; 95% CI, 1.17–23.40; p = 0.043; Pc = NS; [DRBI*04:06] OR = 5.4; 95% CI, 1.59–18.39; p = 0.011; Pc = NS; [DRBI*14:03] OR = 10.0; 95% CI, 1.31–76.56; p = 0.048; Pc = NS). In severe cases of MERS-CoV infection, the frequencies of HLA-C*07:06 and -DRB1*13:01 alleles were higher than those of the controls, but were not significant by Bonferroni's correction ([C*07:06] OR = 5.2; 95% CI, 1.17–23.40; p = 0.043; Pc = NS; [DRB1*13:01] OR = 10.0; 95% CI, 1.31–76.56; p = 0.048; Pc = NS).

### Table 2 Genetic influence of HLA class I and II in MERS patients

| Alleles    | Controls n = 142 (%) | MERS total n = 32 (%) | Moderate/mild n = 16 (%) | Severe n = 16 (%) |
|------------|----------------------|-----------------------|--------------------------|------------------|
| C*01:02    | 48 (33.8) 7 (21.9)   | 1 (6.3)               | 6 (37.5)                 |
| C*07:06    | 6 (4.2)           | 4 (12.5)              | 1 (6.3)                  | 3 (18.8)         |
| C*12:02    | 6 (4.2)           | 3 (9.4)               | 3 (18.8)                 | 0 (0.0)          |
| DRB1*04:06 | 11 (7.7)         | 5 (15.6)              | 5 (31.3)                 | 0 (0.0)          |
| DRB1*13:01 | 2 (1.4)           | 3 (9.4)               | 1 (6.3)                  | 2 (12.5)         |
| DRB1*14:03 | 2 (1.4)           | 2 (6.3)               | 2 (12.5)                 | 0 (0.0)          |
| DQB1*03:02 | 30 (21.1)         | 10 (31.3)             | 9 (56.3)                 | 1 (6.3)          |
| DQB1*06:03 | 2 (1.4)           | 3 (9.4)               | 1 (6.3)                  | 2 (12.5)         |

**Abbreviations:** Pc, Bonferroni’s correction; MERS, Middle East Respiratory Syndrome; NS, not significant.

Controls versus total patients:
- OR = 7.2 (1.16–45.29), p = 0.040, Pc = NS

Controls versus moderate/mild patients:
- OR = 0.1 (0.017–1.018), p = 0.015, Pc = NS;
- OR = 5.2 (1.17–23.40), p = 0.043, Pc = NS;
- OR = 5.4 (1.59–18.39), p = 0.011, Pc = NS;
- OR = 10.0 (1.31–76.56), p = 0.048, Pc = NS;
- OR = 4.8 (1.65–13.95), p = 0.002, Pc = 0.030

Controls versus severe patients:
- OR = 5.2 (1.17–23.40), p = 0.043, Pc = NS;
- OR = 5.4 (1.59–18.39), p = 0.048, Pc = NS;
- OR = 5.4 (1.59–18.39), p = 0.048, Pc = NS

Fisher exact test
HLA-DQB1*06:03 alleles carried statistical significance in the total cases (OR = 7.2; 95% CI, 1.16–45.29; p = 0.040; \( P_\epsilon = \text{NS} \)) and severe cases (OR = 10.0; 95% CI, 1.31–76.56; \( p = 0.048; P_\epsilon = \text{NS} \)); however, there was no significance by the correction (Table 2).

HLA-A and -DPB1 alleles did not show statistical significance in the Korean cohorts compared with those of the controls. HLA-B*01:01 allele frequency increased in the cases of the total and severe groups compared with the control group, but this was not statistically significant by Fisher’s exact test (Table S1-S6).

We investigated the association of HLA class I and II alleles with MERS-CoV in 32 patients with MERS. HLA-DQB1*03:02 showed a significant association with Mo/Mi cases of MERS-CoV infection (OR = 4.8; 95% CI, 1.65–13.95; \( p = 0.002; P_\epsilon = 0.030 \)). Cytokines play a pivotal role in aspirin-exacerbated respiratory disease (AERD).\(^7\) These cytokines are secreted by the major histocompatibility complex class II, which is encoded by HLA class II genes (e.g., HLA-DRB1, -DQB1, and -DPB1).\(^5\) According to pharmacogenetic tests for predicting the efficacy of aspirin desensitization (AD) in patients with respiratory disease exacerbated by aspirin, HLA-DQB1*03:02 expression of nonresponders was significantly lower than that of responders about AD (OR = 0.12; 95% CI, 0.02–0.76; \( p = 0.022 \)). When predicting response to AD, HLA-DQB1*03:02 had the sensitivity of 71.4% and the specificity of 81.8%.\(^1\) The HLA-DQB1*03:02 allele expression in patients with AERD was higher (OR = 5.49; 95% CI, 2.40–12.59; \( p < 0.05 \)). Haplotype expression of HLA-DRB1*04/DQA1*03:01/DQB1*03:02 was higher (OR = 4.25; 95% CI, 1.94–9.29; \( p < 0.05 \)).\(^18\) The HLA-DQB1*03:02 allele is susceptible to AERD in patients.

Several studies have reported that HLA association with SARS-CoV infection is closely related to that of MERS-CoV.\(^9,12,19\) In Saudi Arabia, HLA-DRB1*11:01 and DQB1*02:02 alleles were associated with MERS-CoV infection.\(^15\) Conflicting results for HLA association with SARS-CoV, which is closely related to MERS-CoV, have been reported. While Xiong et al. and Ng et al.\(^9,19\) reported no HLA associations, others have shown an association with HLA-A*46:01.\(^12\)

MERS-CoV, SARS-CoV, and SARS-CoV-2 are the members of the CoV family and belong to the \( \beta \)-CoVs.\(^20\) Because MERS-CoV mainly suppresses the innate immune system, stable transmission is possible in the early stages of infection. By limiting the production of interferons (IFNs) and recruiting neutrophils to the lungs, it can lead to robust production of proinflammatory cytokines and chemokines.\(^21\) A study of coronavirus infection-19 (COVID-19) found that the incidence of lymphopenia was 72%, consistent with SARS-CoV and MERS-CoV. CD4\(^+\) T cells, CD8\(^+\) T cells, and B cells were also reduced in 29%, 29%, and 25% of COVID-19 patients, respectively. However, Natural Killer (NK) cell levels were considerably decreased in 59% of these cases (a higher incidence rate than that found for patients with MERS-CoV or SARS-CoV).\(^22\) This phenomenon has also been found in patients with MERS-CoV or SARS-CoV pneumonia.\(^23\) Lymphopenia occurs in 34% of patients with MERS. Lymphopenia can occur indirectly due to viral attachment of inflammatory mediators or immune disorders. Also, lymphopenia may develop when lymphocytes effuse into inflammatory lung tissue.\(^24\)

To date, it is not clear why some patients suffer from MERS-CoV. Treatment strategies based on current research on the HLA gene and its association with MERS-CoV could provide potential therapeutic targets.

**ACKNOWLEDGMENTS**

This study was supported by a grant from the National Medical Center of the Republic of Korea (grant number NMC2018-MS-01), the Korean Health Technology R&D Project of the Ministry for Health & Welfare of the Republic of Korea (grant number HI14C3417), and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number 2019R1I1A1A01064049).

**CONFLICT OF INTERESTS**

The authors declare that there are no conflict of interests.

**AUTHOR CONTRIBUTIONS**

Baek In-Cheol, Lim Dong-Gyun, and Kim Tai-Gyu contributed to the conception of the study; Baek In-Cheol was involved in data acquisition and formal analysis; Baek In-Cheol, Lim Dong-Gyun, and Kim Tai-Gyu were involved in funding acquisition; Baek In-Cheol, Choi Eun-Jeong, Shin Dong-Hwan, and Kim Hyoung-Jae performed the investigation and methodology; Lim Dong-Gyun and Kim Tai-Gyu were involved in project administration; Shin Hyoung-Shik and Lim Dong-Gyun acquired resources; Kim Tai-Gyu provided supervision; Baek In-Cheol, Shin Dong-Hwan, Kim Hyoung-Jae, and Choi Haeyoun were involved in validation; Baek In-Cheol wrote the original draft, as well as reviewed and edited the manuscript.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
REFERENCES

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820. doi:10.1056/NEJMoA1211721

2. Sikkema RS, Farag E, Islam M, et al. Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review. Epidemiol Infect. 2019;147:e84. doi:10.1017/s095026881800345x

3. Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 2015;20(25):7-13. doi:10.2807/1560-7917.es2015.20.25.21163

4. Ki M. 2015 MERS outbreak in Korea: hospital-to-hospital transmission. Epidemiol Health. 2015;37:e2015033. doi:10.4178/eph/e2015033

5. Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect. 2017;95(2):207-213. doi:10.1016/j.jhin.2016.10.008

6. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med. 2000;343(10):702-709. doi:10.1056/nejm200009073431006

7. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534. doi:10.1038/nrmicro.2016.81

8. Di Maria E, Latini A, Borgia J, Novelli G. Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis. Hum Genomics. 2020;14(1):30. doi:10.1186/s40246-020-00280-6

9. Xiong P, Zeng X, Song MS, et al. Lack of association between HLA-A, -B and -DRB1 alleles and the development of SARS: a cohort of 95 SARS-recovered individuals in a population of Guangdong, southern China. Int J Immunogenet. 2008;35(1):69-74. doi:10.1111/j.1744-331X.2007.00741.x

10. Wang SF, Chen KH, Chen M, et al. Human-leukocyte antigen class I CW 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. Viral Immunol. 2011;24(5):421-426. doi:10.1089/vim.2011.0024

11. Keicho N, Itoyama S, Kashiwase K, et al. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum Immunol. 2009;70(7):527-531. doi:10.1016/j.humimm.2009.05.006

12. Lin M, Tseng HK, Trejaut JA, et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. 2003;4:9. doi:10.1186/1471-2350-4-9

13. Chen YM, Liang SY, Shih YP, et al. Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. J Clin Microbiol. 2006;44(2):359-365. doi:10.1128/jcm.44.2.359-365.2006

14. Ng MH, Lau KM, Li L, et al. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis. 2004;190(3):515-518. doi:10.1086/421523

15. Hajeer AH, Balkhy H, Johani S, Yousef MZ, Arabi Y. Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection. Ann Thorac Med. 2016;11(3):211-213. doi:10.4103/1817-1737.185756

16. Shin DH, Baek IC, Kim HJ, et al. HLA alleles, especially amino-acid signatures of HLA-DPB1, might contribute to the molecular pathogenesis of early-onset autoimmune thyroid disease. PLOS One. 2019;14(5):e0216941. doi:10.1371/journal.pone.0216941

17. Esmaeilzadeh H, Nabavi M, Aryan Z, Amirzargar AA. Pharmacogenetic tests to predict the efficacy of aspirin desensitization in patients with aspirin-exacerbated respiratory diseases; HLA-DQB302. Expert Rev Respir Med. 2015;9(5):511-518. doi:10.1586/17476348.2015.1081062

18. Esmaeilzadeh H, Nabavi M, Amirzargar AA, et al. HLA-DRB1 and HLA-DQ genetic variability in patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2015;29(3):e63-e69. doi:10.2506/ajra.2015.29.4154

19. Ng MH, Cheng SH, Lau KM, et al. Immunogenetics in SARS: a case-control study. Hong Kong Med J. 2010;16(5 Suppl 4):29-33.

20. Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40(1):68-76. doi:10.1080/01652176.2020.1727993

21. Channappanavar R, Fehr AR, Zheng J, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9):3625-3639. doi:10.1172/jci126363

22. Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762-1769. doi:10.1093/infdis/jiaa150

23. He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9(6):323-330. doi:10.1016/j.ijid.2004.07.014

24. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of
SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Baek I-C, Choi E-J, Shin D-H, et al. Association of HLA class I and II genes with Middle East Respiratory Syndrome coronavirus infection in Koreans. Immun Inflamm Dis. 2022;10:111-116. https://doi.org/10.1002/iid3.541